|
It was reported that the patient had weakness, lethargy, shortness of breath, and lightheadedness in the setting of pulmonary embolism and pneumonia with subsequent transition to comfort care at the patient's request.The patient passed away on comfort care.The outcome was not considered device or therapy related.An autopsy was not performed.The device was not explanted and will not be returned for evaluation.
|
|
Manufacturer¿s investigation conclusion: a direct correlation between heartmate ii left ventricular assist system (lvas), serial number: (b)(6) and the reported patient outcome could not be conclusively established through this evaluation.The device was not explanted and would not be returned for evaluation.The relevant sections of the device history records for (b)(6) were reviewed and showed no deviations from manufacturing or quality assurance specifications.The current revision of the instructions for use (ifu) can be found on the eifu page of the abbott website.The heartmate ii lvas ifu, rev.A is currently available.Section 1 of the ifu, ¿introduction¿, lists potential adverse events, including peripheral thromboembolic events and death, that may be associated with the use of the heartmate ii left ventricular assist system.Section 6, ¿patient care and management,¿ lists thromboembolism as a potential late postimplant complication.Under ¿anticoagulation," this section also provides the recommended anticoagulation regimen, including international normalized ratio (inr) range, as well as suggested anticoagulation modifications.No further information was provided.The manufacturer is closing the file on this event.
|